Laura James
Concepts (571)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 63 | 2025 | 277 | 11.870 |
Why?
| | Analgesics, Non-Narcotic | 28 | 2025 | 120 | 4.990 |
Why?
| | Drug Overdose | 17 | 2024 | 170 | 2.900 |
Why?
| | Liver | 25 | 2025 | 1150 | 2.830 |
Why?
| | Liver Failure, Acute | 13 | 2024 | 57 | 2.330 |
Why?
| | Hepatocytes | 16 | 2018 | 188 | 2.260 |
Why?
| | Liver Regeneration | 9 | 2019 | 46 | 1.800 |
Why?
| | MicroRNAs | 5 | 2020 | 397 | 1.250 |
Why?
| | Alanine Transaminase | 17 | 2023 | 118 | 1.190 |
Why?
| | Male | 89 | 2025 | 27435 | 1.110 |
Why?
| | Adolescent | 47 | 2025 | 6907 | 1.100 |
Why?
| | Cytochrome P-450 CYP2E1 | 4 | 2020 | 111 | 1.060 |
Why?
| | Acetylcysteine | 13 | 2019 | 104 | 1.060 |
Why?
| | Proton Pump Inhibitors | 7 | 2024 | 95 | 1.060 |
Why?
| | Mitochondria, Liver | 10 | 2015 | 69 | 1.030 |
Why?
| | Child | 44 | 2025 | 7379 | 0.980 |
Why?
| | Oxidative Stress | 12 | 2023 | 819 | 0.960 |
Why?
| | Cytochrome P-450 CYP3A | 3 | 2020 | 78 | 0.960 |
Why?
| | Humans | 108 | 2026 | 53230 | 0.930 |
Why?
| | Chromatography, High Pressure Liquid | 10 | 2016 | 333 | 0.840 |
Why?
| | Child, Preschool | 29 | 2024 | 4162 | 0.820 |
Why?
| | Cytokines | 8 | 2012 | 627 | 0.800 |
Why?
| | Female | 68 | 2025 | 28782 | 0.800 |
Why?
| | Attitude | 2 | 2021 | 72 | 0.790 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 62 | 0.780 |
Why?
| | Animals | 42 | 2025 | 13526 | 0.770 |
Why?
| | Asthma | 4 | 2022 | 319 | 0.760 |
Why?
| | Proteins | 4 | 2016 | 351 | 0.750 |
Why?
| | Rape | 1 | 2022 | 18 | 0.730 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 46 | 0.730 |
Why?
| | Crime Victims | 1 | 2022 | 59 | 0.680 |
Why?
| | Health Facilities | 1 | 2021 | 40 | 0.660 |
Why?
| | Mice | 30 | 2025 | 5982 | 0.660 |
Why?
| | Sex Offenses | 1 | 2022 | 97 | 0.650 |
Why?
| | Cysteine | 7 | 2024 | 50 | 0.640 |
Why?
| | Inflammation | 3 | 2020 | 652 | 0.630 |
Why?
| | Naphthalenes | 9 | 2018 | 121 | 0.620 |
Why?
| | Cytochrome P-450 CYP1A2 | 4 | 2020 | 38 | 0.620 |
Why?
| | Indoles | 9 | 2018 | 280 | 0.620 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2011 | 189 | 0.610 |
Why?
| | Liver Diseases | 4 | 2023 | 81 | 0.610 |
Why?
| | Health Services Accessibility | 2 | 2021 | 477 | 0.600 |
Why?
| | Bronchoconstriction | 1 | 2019 | 6 | 0.590 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 19 | 0.570 |
Why?
| | Mitochondria | 2 | 2020 | 446 | 0.560 |
Why?
| | Aspartate Aminotransferases | 8 | 2015 | 46 | 0.560 |
Why?
| | Bronchodilator Agents | 1 | 2019 | 73 | 0.550 |
Why?
| | Radius | 1 | 2018 | 27 | 0.540 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 75 | 0.500 |
Why?
| | Immunoassay | 1 | 2016 | 23 | 0.500 |
Why?
| | Serum | 1 | 2016 | 32 | 0.500 |
Why?
| | Mice, Inbred C57BL | 16 | 2025 | 1925 | 0.500 |
Why?
| | Dose-Response Relationship, Drug | 12 | 2019 | 1367 | 0.490 |
Why?
| | Imines | 4 | 2025 | 16 | 0.490 |
Why?
| | Gastroesophageal Reflux | 4 | 2018 | 51 | 0.490 |
Why?
| | Benzoquinones | 4 | 2025 | 33 | 0.490 |
Why?
| | Anti-Bacterial Agents | 6 | 2023 | 830 | 0.480 |
Why?
| | Tandem Mass Spectrometry | 7 | 2026 | 254 | 0.460 |
Why?
| | Infant | 21 | 2022 | 3805 | 0.460 |
Why?
| | Young Adult | 17 | 2023 | 4511 | 0.460 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 155 | 0.460 |
Why?
| | Lung | 1 | 2019 | 481 | 0.450 |
Why?
| | Reactive Nitrogen Species | 3 | 2015 | 23 | 0.450 |
Why?
| | Keratin-18 | 2 | 2021 | 14 | 0.450 |
Why?
| | Proliferating Cell Nuclear Antigen | 4 | 2019 | 69 | 0.450 |
Why?
| | Bile Acids and Salts | 1 | 2015 | 81 | 0.450 |
Why?
| | HMGB1 Protein | 2 | 2021 | 22 | 0.450 |
Why?
| | Mass Spectrometry | 4 | 2014 | 294 | 0.440 |
Why?
| | Tyrosine | 4 | 2007 | 92 | 0.430 |
Why?
| | Mice, Inbred Strains | 7 | 2019 | 163 | 0.430 |
Why?
| | Isoniazid | 1 | 2014 | 28 | 0.420 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 124 | 0.420 |
Why?
| | Carnitine | 1 | 2014 | 67 | 0.400 |
Why?
| | Adult | 24 | 2025 | 14534 | 0.400 |
Why?
| | Disease Models, Animal | 7 | 2020 | 1517 | 0.400 |
Why?
| | Autoantibodies | 1 | 2014 | 120 | 0.390 |
Why?
| | Trifluoperazine | 1 | 2012 | 6 | 0.380 |
Why?
| | Sensitivity and Specificity | 9 | 2016 | 867 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 1180 | 0.370 |
Why?
| | Viperidae | 1 | 2012 | 5 | 0.370 |
Why?
| | Crotalid Venoms | 1 | 2012 | 8 | 0.370 |
Why?
| | Antivenins | 1 | 2012 | 9 | 0.370 |
Why?
| | Immunoglobulin Fragments | 1 | 2012 | 14 | 0.370 |
Why?
| | Snake Bites | 1 | 2012 | 14 | 0.370 |
Why?
| | Anti-Ulcer Agents | 3 | 2007 | 22 | 0.370 |
Why?
| | Substance Abuse Detection | 3 | 2026 | 93 | 0.360 |
Why?
| | Echinomycin | 1 | 2011 | 6 | 0.360 |
Why?
| | Hepatitis, Viral, Human | 2 | 2024 | 11 | 0.360 |
Why?
| | Prospective Studies | 12 | 2024 | 2411 | 0.350 |
Why?
| | Cannabinoids | 5 | 2013 | 104 | 0.350 |
Why?
| | Enzyme Inhibitors | 5 | 2019 | 371 | 0.350 |
Why?
| | Half-Life | 6 | 2019 | 86 | 0.340 |
Why?
| | Necrosis | 6 | 2019 | 169 | 0.340 |
Why?
| | Spider Venoms | 1 | 2011 | 6 | 0.340 |
Why?
| | Hospitalization | 4 | 2017 | 749 | 0.340 |
Why?
| | Hypersensitivity | 1 | 2012 | 83 | 0.340 |
Why?
| | Middle Aged | 18 | 2024 | 13419 | 0.340 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2011 | 46 | 0.330 |
Why?
| | Indocyanine Green | 1 | 2010 | 29 | 0.330 |
Why?
| | Arkansas | 8 | 2025 | 2068 | 0.320 |
Why?
| | Students | 2 | 2023 | 249 | 0.320 |
Why?
| | Macrolides | 3 | 2022 | 17 | 0.310 |
Why?
| | Methamphetamine | 3 | 2013 | 190 | 0.310 |
Why?
| | Models, Biological | 7 | 2024 | 737 | 0.310 |
Why?
| | Central Nervous System Stimulants | 3 | 2013 | 201 | 0.300 |
Why?
| | Triazoles | 3 | 2022 | 114 | 0.290 |
Why?
| | Metabolomics | 3 | 2015 | 155 | 0.290 |
Why?
| | Protein Binding | 5 | 2017 | 670 | 0.290 |
Why?
| | Homeostasis | 3 | 2020 | 209 | 0.280 |
Why?
| | Chemokines | 2 | 2010 | 78 | 0.270 |
Why?
| | Research Subjects | 2 | 2019 | 53 | 0.270 |
Why?
| | Chemokine CCL2 | 2 | 2005 | 66 | 0.270 |
Why?
| | Community-Based Participatory Research | 2 | 2021 | 203 | 0.270 |
Why?
| | Glutathione | 5 | 2025 | 303 | 0.270 |
Why?
| | Poisoning | 2 | 2006 | 21 | 0.260 |
Why?
| | Interleukin-6 | 3 | 2012 | 272 | 0.260 |
Why?
| | Chromatography, Liquid | 7 | 2026 | 245 | 0.260 |
Why?
| | Area Under Curve | 8 | 2019 | 185 | 0.260 |
Why?
| | Interleukin-8 | 3 | 2012 | 85 | 0.250 |
Why?
| | Pandemics | 2 | 2022 | 595 | 0.250 |
Why?
| | Caustics | 1 | 2006 | 5 | 0.250 |
Why?
| | Burns, Chemical | 1 | 2006 | 9 | 0.250 |
Why?
| | Signal Transduction | 5 | 2019 | 1748 | 0.250 |
Why?
| | Cell Death | 4 | 2020 | 171 | 0.250 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 3 | 0.240 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 26 | 0.240 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 1723 | 0.240 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 1003 | 0.230 |
Why?
| | Antidotes | 4 | 2011 | 27 | 0.230 |
Why?
| | Infant, Premature | 4 | 2016 | 331 | 0.230 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 38 | 0.230 |
Why?
| | Liver Function Tests | 2 | 2002 | 47 | 0.230 |
Why?
| | Predictive Value of Tests | 5 | 2016 | 934 | 0.230 |
Why?
| | Reactive Oxygen Species | 3 | 2015 | 421 | 0.230 |
Why?
| | Peroxynitrous Acid | 2 | 2007 | 33 | 0.220 |
Why?
| | Infant, Newborn | 10 | 2018 | 2913 | 0.220 |
Why?
| | Cytochrome P-450 Enzyme System | 3 | 2015 | 191 | 0.220 |
Why?
| | Up-Regulation | 4 | 2018 | 456 | 0.210 |
Why?
| | Universities | 2 | 2023 | 186 | 0.210 |
Why?
| | Immunohistochemistry | 3 | 2012 | 975 | 0.210 |
Why?
| | Ion Channels | 1 | 2004 | 70 | 0.210 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 34 | 0.210 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2024 | 56 | 0.210 |
Why?
| | Gastric Acidity Determination | 1 | 2003 | 12 | 0.210 |
Why?
| | Biotransformation | 4 | 2015 | 84 | 0.210 |
Why?
| | Aminoglycosides | 1 | 2023 | 20 | 0.210 |
Why?
| | Glucuronosyltransferase | 3 | 2017 | 121 | 0.200 |
Why?
| | Diagnosis, Differential | 4 | 2024 | 1038 | 0.200 |
Why?
| | Medication Adherence | 1 | 2024 | 136 | 0.190 |
Why?
| | Administration, Oral | 7 | 2018 | 456 | 0.190 |
Why?
| | Pilot Projects | 4 | 2021 | 726 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 238 | 0.190 |
Why?
| | Designer Drugs | 2 | 2013 | 22 | 0.190 |
Why?
| | Granzymes | 2 | 2020 | 11 | 0.190 |
Why?
| | Vitamins | 1 | 2022 | 64 | 0.190 |
Why?
| | Cell Line | 4 | 2017 | 1016 | 0.180 |
Why?
| | Digestive System | 1 | 2002 | 12 | 0.180 |
Why?
| | Pneumonia, Bacterial | 1 | 2022 | 31 | 0.180 |
Why?
| | Community-Acquired Infections | 1 | 2022 | 42 | 0.180 |
Why?
| | Aged | 7 | 2024 | 10429 | 0.180 |
Why?
| | Obesity | 2 | 2022 | 1204 | 0.180 |
Why?
| | Vitamin D | 1 | 2022 | 91 | 0.180 |
Why?
| | Gastrointestinal Agents | 1 | 2002 | 41 | 0.180 |
Why?
| | Phosphatidic Acids | 2 | 2019 | 8 | 0.180 |
Why?
| | Retrospective Studies | 9 | 2024 | 6819 | 0.180 |
Why?
| | Parents | 1 | 2025 | 341 | 0.180 |
Why?
| | Photography | 1 | 2021 | 32 | 0.170 |
Why?
| | Microsomes, Liver | 4 | 2015 | 183 | 0.170 |
Why?
| | Anti-Infective Agents | 2 | 2013 | 107 | 0.170 |
Why?
| | United States | 7 | 2022 | 5409 | 0.170 |
Why?
| | Metabolic Clearance Rate | 5 | 2018 | 66 | 0.170 |
Why?
| | Dried Blood Spot Testing | 2 | 2018 | 5 | 0.170 |
Why?
| | Sexual Behavior | 1 | 2022 | 142 | 0.170 |
Why?
| | Oxidation-Reduction | 6 | 2023 | 333 | 0.170 |
Why?
| | Gastrointestinal Diseases | 1 | 2002 | 130 | 0.170 |
Why?
| | Bayes Theorem | 3 | 2012 | 120 | 0.170 |
Why?
| | Healthcare Disparities | 1 | 2024 | 312 | 0.160 |
Why?
| | Heart Arrest | 1 | 2022 | 144 | 0.160 |
Why?
| | Hydroxyurea | 1 | 2020 | 29 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2021 | 3494 | 0.160 |
Why?
| | Substance-Related Disorders | 3 | 2022 | 630 | 0.160 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 181 | 0.160 |
Why?
| | Histamine H2 Antagonists | 3 | 2005 | 28 | 0.150 |
Why?
| | Recombinant Proteins | 4 | 2018 | 489 | 0.150 |
Why?
| | Brain | 3 | 2025 | 1350 | 0.150 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 198 | 0.150 |
Why?
| | Binding Sites | 2 | 2017 | 373 | 0.150 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2019 | 11 | 0.150 |
Why?
| | Lipids | 1 | 2020 | 163 | 0.150 |
Why?
| | Prothrombin Time | 3 | 2005 | 18 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 630 | 0.150 |
Why?
| | Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 4 | 0.150 |
Why?
| | Time Factors | 5 | 2013 | 2991 | 0.150 |
Why?
| | Carbachol | 1 | 2019 | 26 | 0.150 |
Why?
| | ortho-Aminobenzoates | 1 | 2019 | 6 | 0.150 |
Why?
| | Mice, Knockout | 4 | 2011 | 910 | 0.150 |
Why?
| | Stress, Physiological | 1 | 2020 | 184 | 0.150 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 44 | 0.150 |
Why?
| | Respiratory Hypersensitivity | 1 | 2019 | 17 | 0.150 |
Why?
| | Child, Hospitalized | 1 | 2019 | 33 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 246 | 0.150 |
Why?
| | Drug Administration Schedule | 4 | 2021 | 370 | 0.150 |
Why?
| | Disclosure | 1 | 2019 | 40 | 0.140 |
Why?
| | Body Weight | 3 | 2018 | 524 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2018 | 1212 | 0.140 |
Why?
| | Bacterial Infections | 2 | 2017 | 96 | 0.140 |
Why?
| | Seroepidemiologic Studies | 3 | 2023 | 43 | 0.140 |
Why?
| | Cannabidiol | 1 | 2019 | 44 | 0.140 |
Why?
| | Research Personnel | 1 | 2019 | 73 | 0.140 |
Why?
| | Oropharynx | 2 | 2009 | 13 | 0.140 |
Why?
| | Ampicillin | 1 | 2018 | 5 | 0.140 |
Why?
| | Albuterol | 1 | 2019 | 54 | 0.140 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 27 | 0.140 |
Why?
| | Protein Biosynthesis | 2 | 2017 | 268 | 0.140 |
Why?
| | Information Dissemination | 1 | 2019 | 85 | 0.140 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Health Status Disparities | 1 | 2021 | 221 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2019 | 5595 | 0.140 |
Why?
| | Education, Nonprofessional | 1 | 2017 | 8 | 0.140 |
Why?
| | Phosphatidate Phosphatase | 1 | 2018 | 24 | 0.140 |
Why?
| | Human Experimentation | 1 | 2017 | 10 | 0.140 |
Why?
| | Mass Screening | 1 | 2021 | 362 | 0.140 |
Why?
| | Sirtuin 1 | 1 | 2017 | 29 | 0.140 |
Why?
| | Sulfonamides | 1 | 2019 | 139 | 0.130 |
Why?
| | Teicoplanin | 1 | 2017 | 4 | 0.130 |
Why?
| | Teaching Materials | 1 | 2017 | 31 | 0.130 |
Why?
| | 3' Untranslated Regions | 1 | 2017 | 55 | 0.130 |
Why?
| | Patient Participation | 1 | 2018 | 72 | 0.130 |
Why?
| | Health Services Research | 1 | 2018 | 153 | 0.130 |
Why?
| | Absorptiometry, Photon | 1 | 2018 | 160 | 0.130 |
Why?
| | Reading | 1 | 2017 | 74 | 0.130 |
Why?
| | Rural Population | 2 | 2021 | 596 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2024 | 1049 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 533 | 0.130 |
Why?
| | Electrochemical Techniques | 1 | 2016 | 9 | 0.130 |
Why?
| | Anthropometry | 2 | 2015 | 101 | 0.120 |
Why?
| | Comprehension | 1 | 2017 | 115 | 0.120 |
Why?
| | Age Factors | 3 | 2015 | 1136 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2018 | 250 | 0.120 |
Why?
| | Saliva | 1 | 2016 | 56 | 0.120 |
Why?
| | Vitamin A | 1 | 2016 | 16 | 0.120 |
Why?
| | Liver Failure | 1 | 2016 | 21 | 0.120 |
Why?
| | Amphetamine | 2 | 2013 | 36 | 0.120 |
Why?
| | Nitric Oxide Synthase Type I | 2 | 2015 | 10 | 0.120 |
Why?
| | Injections, Intravenous | 3 | 2012 | 129 | 0.120 |
Why?
| | Blood Proteins | 2 | 2006 | 84 | 0.120 |
Why?
| | Point-of-Care Systems | 1 | 2016 | 68 | 0.120 |
Why?
| | Caffeine | 1 | 2016 | 64 | 0.120 |
Why?
| | Blood Pressure Monitors | 1 | 2015 | 10 | 0.120 |
Why?
| | Biomedical Research | 1 | 2019 | 267 | 0.120 |
Why?
| | Taurodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Glycodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Guanidines | 1 | 2015 | 28 | 0.120 |
Why?
| | Glycochenodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Keratin-8 | 1 | 2015 | 3 | 0.120 |
Why?
| | Styrene | 1 | 2015 | 9 | 0.120 |
Why?
| | Bone Density | 1 | 2018 | 397 | 0.120 |
Why?
| | Prodrugs | 2 | 2012 | 35 | 0.110 |
Why?
| | Delayed-Action Preparations | 2 | 2012 | 58 | 0.110 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 71 | 0.110 |
Why?
| | Solid Phase Extraction | 2 | 2013 | 14 | 0.110 |
Why?
| | Breast Neoplasms | 1 | 2024 | 1222 | 0.110 |
Why?
| | Tablets | 3 | 2013 | 32 | 0.110 |
Why?
| | Immunity, Innate | 1 | 2016 | 112 | 0.110 |
Why?
| | Cross-Over Studies | 2 | 2012 | 241 | 0.110 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.110 |
Why?
| | Nitrates | 2 | 2011 | 30 | 0.110 |
Why?
| | Administration, Intravenous | 3 | 2019 | 73 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2017 | 1569 | 0.110 |
Why?
| | Famotidine | 2 | 2005 | 11 | 0.100 |
Why?
| | Discriminant Analysis | 1 | 2014 | 26 | 0.100 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 44 | 0.100 |
Why?
| | Environmental Pollutants | 1 | 2015 | 110 | 0.100 |
Why?
| | Urinalysis | 1 | 2014 | 33 | 0.100 |
Why?
| | Superoxide Dismutase | 2 | 2011 | 122 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 392 | 0.100 |
Why?
| | Wounds, Stab | 1 | 2013 | 5 | 0.100 |
Why?
| | Cannabis | 2 | 2019 | 155 | 0.100 |
Why?
| | Cyclosporine | 2 | 2011 | 64 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2013 | 25 | 0.100 |
Why?
| | Neck Injuries | 1 | 2013 | 21 | 0.100 |
Why?
| | Fentanyl | 1 | 2014 | 40 | 0.100 |
Why?
| | Benzoflavones | 1 | 2013 | 3 | 0.100 |
Why?
| | Sulfaphenazole | 1 | 2013 | 4 | 0.100 |
Why?
| | Kinetics | 4 | 2018 | 607 | 0.100 |
Why?
| | Nonlinear Dynamics | 2 | 2012 | 18 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 505 | 0.100 |
Why?
| | Cohort Studies | 3 | 2019 | 1557 | 0.100 |
Why?
| | Self-Injurious Behavior | 1 | 2013 | 34 | 0.100 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2012 | 17 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 19 | 0.100 |
Why?
| | Myoglobin | 1 | 2013 | 25 | 0.100 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2012 | 14 | 0.100 |
Why?
| | Neurotoxicity Syndromes | 1 | 2013 | 46 | 0.090 |
Why?
| | Indicators and Reagents | 1 | 2012 | 36 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 25 | 0.090 |
Why?
| | Dinoprostone | 1 | 2012 | 43 | 0.090 |
Why?
| | Permeability | 1 | 2012 | 70 | 0.090 |
Why?
| | Flushing | 1 | 2012 | 5 | 0.090 |
Why?
| | Piperacillin | 1 | 2012 | 24 | 0.090 |
Why?
| | Fasting | 1 | 2012 | 76 | 0.090 |
Why?
| | Antibodies, Viral | 2 | 2023 | 109 | 0.090 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2012 | 19 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2014 | 321 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2012 | 34 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2012 | 107 | 0.090 |
Why?
| | Erythema | 1 | 2012 | 38 | 0.090 |
Why?
| | Insulin | 1 | 2014 | 493 | 0.090 |
Why?
| | Metronidazole | 1 | 2012 | 32 | 0.090 |
Why?
| | Exanthema | 1 | 2012 | 33 | 0.090 |
Why?
| | Pruritus | 1 | 2012 | 44 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 203 | 0.090 |
Why?
| | Cardiopulmonary Bypass | 1 | 2012 | 91 | 0.090 |
Why?
| | Ketamine | 1 | 2012 | 62 | 0.090 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 2012 | 46 | 0.090 |
Why?
| | Neutropenia | 1 | 2012 | 113 | 0.090 |
Why?
| | Vancomycin | 1 | 2012 | 91 | 0.090 |
Why?
| | Sex Factors | 1 | 2014 | 747 | 0.090 |
Why?
| | Cellulitis | 1 | 2011 | 11 | 0.090 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2012 | 123 | 0.090 |
Why?
| | Neuroprotective Agents | 1 | 2012 | 101 | 0.090 |
Why?
| | Nitroimidazoles | 1 | 2011 | 16 | 0.090 |
Why?
| | Anemia, Hemolytic | 1 | 2011 | 10 | 0.090 |
Why?
| | Rhabdomyolysis | 1 | 2011 | 11 | 0.090 |
Why?
| | Hypertension | 2 | 2015 | 554 | 0.080 |
Why?
| | Hair | 1 | 2011 | 29 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 164 | 0.080 |
Why?
| | Coloring Agents | 1 | 2010 | 65 | 0.080 |
Why?
| | Brain Injuries | 1 | 2012 | 160 | 0.080 |
Why?
| | Muscular Diseases | 1 | 2011 | 64 | 0.080 |
Why?
| | Kidney Transplantation | 1 | 2012 | 203 | 0.080 |
Why?
| | Interleukin-10 | 2 | 2012 | 81 | 0.080 |
Why?
| | Immunoblotting | 1 | 2010 | 118 | 0.080 |
Why?
| | Liver Circulation | 1 | 2010 | 21 | 0.080 |
Why?
| | Sodium Oxybate | 1 | 2009 | 11 | 0.080 |
Why?
| | Butylene Glycols | 1 | 2009 | 14 | 0.080 |
Why?
| | Play and Playthings | 1 | 2009 | 15 | 0.080 |
Why?
| | Coma | 1 | 2009 | 17 | 0.080 |
Why?
| | Blood Pressure | 1 | 2012 | 518 | 0.080 |
Why?
| | Linear Models | 2 | 2012 | 287 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 230 | 0.080 |
Why?
| | Databases as Topic | 1 | 2009 | 38 | 0.080 |
Why?
| | Foreign Bodies | 1 | 2009 | 66 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2011 | 253 | 0.070 |
Why?
| | Environmental Exposure | 1 | 2011 | 222 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 2008 | 26 | 0.070 |
Why?
| | Drug Compounding | 1 | 2008 | 26 | 0.070 |
Why?
| | Incidence | 1 | 2012 | 1085 | 0.070 |
Why?
| | Cesium | 1 | 2008 | 8 | 0.070 |
Why?
| | Chlorides | 1 | 2008 | 42 | 0.070 |
Why?
| | DNA | 1 | 2011 | 535 | 0.070 |
Why?
| | Probability | 1 | 2008 | 171 | 0.070 |
Why?
| | Registries | 2 | 2024 | 652 | 0.070 |
Why?
| | Macrophages | 2 | 2017 | 380 | 0.070 |
Why?
| | Chloroform | 1 | 2007 | 5 | 0.070 |
Why?
| | Analgesics, Opioid | 1 | 2014 | 622 | 0.070 |
Why?
| | Models, Statistical | 1 | 2009 | 229 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2012 | 1583 | 0.070 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 24 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 211 | 0.070 |
Why?
| | Sulfuric Acids | 1 | 2006 | 8 | 0.060 |
Why?
| | Electrocardiography | 1 | 2008 | 273 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2007 | 547 | 0.060 |
Why?
| | Aerobiosis | 1 | 2006 | 13 | 0.060 |
Why?
| | Genotype | 3 | 2018 | 563 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2011 | 399 | 0.060 |
Why?
| | Emergency Medicine | 1 | 2006 | 50 | 0.060 |
Why?
| | Hepatitis C, Chronic | 2 | 2018 | 89 | 0.060 |
Why?
| | Toxicity Tests | 1 | 2006 | 57 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2015 | 1219 | 0.060 |
Why?
| | Antioxidants | 2 | 2023 | 264 | 0.060 |
Why?
| | Phosphorylation | 2 | 2019 | 533 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2006 | 187 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 233 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2018 | 561 | 0.060 |
Why?
| | Metabolic Detoxication, Phase II | 2 | 2017 | 11 | 0.060 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2004 | 18 | 0.060 |
Why?
| | Child Abuse | 1 | 2006 | 145 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2024 | 68 | 0.050 |
Why?
| | Kupffer Cells | 1 | 2003 | 12 | 0.050 |
Why?
| | Computer Simulation | 2 | 2017 | 290 | 0.050 |
Why?
| | Glutathione Disulfide | 1 | 2003 | 38 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2015 | 120 | 0.050 |
Why?
| | Models, Chemical | 2 | 2015 | 65 | 0.050 |
Why?
| | Risk Assessment | 1 | 2008 | 1368 | 0.050 |
Why?
| | Superoxides | 1 | 2003 | 46 | 0.050 |
Why?
| | Pyruvic Acid | 1 | 2023 | 20 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2024 | 134 | 0.050 |
Why?
| | Papillomavirus Vaccines | 1 | 2025 | 74 | 0.050 |
Why?
| | Alanine | 1 | 2023 | 43 | 0.050 |
Why?
| | Omeprazole | 1 | 2003 | 17 | 0.050 |
Why?
| | Mixed Function Oxygenases | 1 | 2003 | 25 | 0.050 |
Why?
| | Ischemia | 1 | 2024 | 158 | 0.050 |
Why?
| | Injections, Intraperitoneal | 1 | 2003 | 55 | 0.050 |
Why?
| | Prognosis | 3 | 2015 | 2118 | 0.050 |
Why?
| | Safety | 1 | 2003 | 78 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 134 | 0.050 |
Why?
| | Oxygen | 1 | 2006 | 338 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2003 | 121 | 0.050 |
Why?
| | Radiographic Image Enhancement | 1 | 2003 | 29 | 0.050 |
Why?
| | Genetic Variation | 1 | 2024 | 223 | 0.050 |
Why?
| | Drug Interactions | 1 | 2003 | 196 | 0.050 |
Why?
| | Logistic Models | 2 | 2018 | 947 | 0.050 |
Why?
| | Pediatrics | 1 | 2006 | 307 | 0.050 |
Why?
| | Tibial Fractures | 1 | 2003 | 34 | 0.050 |
Why?
| | Molecular Structure | 2 | 2013 | 320 | 0.050 |
Why?
| | Papillomavirus Infections | 1 | 2025 | 177 | 0.050 |
Why?
| | Vaccination | 1 | 2025 | 310 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2015 | 44 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2024 | 174 | 0.050 |
Why?
| | Hydroxylation | 2 | 2012 | 64 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2003 | 262 | 0.050 |
Why?
| | Neoplasms | 1 | 2012 | 1334 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2003 | 233 | 0.040 |
Why?
| | Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.040 |
Why?
| | Death, Sudden, Cardiac | 1 | 2022 | 55 | 0.040 |
Why?
| | Psychotropic Drugs | 1 | 2022 | 79 | 0.040 |
Why?
| | Databases, Factual | 1 | 2024 | 742 | 0.040 |
Why?
| | Uncertainty | 1 | 2021 | 46 | 0.040 |
Why?
| | Apoptosis | 1 | 2006 | 1139 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2023 | 774 | 0.040 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 210 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 523 | 0.040 |
Why?
| | Gestational Age | 2 | 2012 | 394 | 0.040 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 34 | 0.040 |
Why?
| | Decision Making | 1 | 2002 | 278 | 0.040 |
Why?
| | Australia | 1 | 2019 | 93 | 0.040 |
Why?
| | Risk Factors | 3 | 2012 | 4017 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 147 | 0.040 |
Why?
| | Research Design | 1 | 2021 | 373 | 0.040 |
Why?
| | Tissue Distribution | 2 | 2013 | 174 | 0.040 |
Why?
| | Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| | Qualitative Research | 1 | 2021 | 384 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 107 | 0.030 |
Why?
| | Mallory Bodies | 1 | 2018 | 1 | 0.030 |
Why?
| | Metagenomics | 1 | 2018 | 41 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2018 | 11 | 0.030 |
Why?
| | Acute-Phase Reaction | 1 | 2018 | 8 | 0.030 |
Why?
| | DNA, Viral | 1 | 2018 | 136 | 0.030 |
Why?
| | Pregnancy | 1 | 2025 | 2608 | 0.030 |
Why?
| | RNA, Viral | 1 | 2018 | 123 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 83 | 0.030 |
Why?
| | Ethics, Research | 1 | 2017 | 39 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 90 | 0.030 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 2011 | 71 | 0.030 |
Why?
| | Rats | 2 | 2014 | 3162 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2018 | 127 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 97 | 0.030 |
Why?
| | Glucuronides | 1 | 2017 | 48 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 235 | 0.030 |
Why?
| | Communication | 1 | 2019 | 263 | 0.030 |
Why?
| | Transfection | 1 | 2017 | 359 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 180 | 0.030 |
Why?
| | Plant Extracts | 1 | 2019 | 200 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2017 | 163 | 0.030 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2016 | 35 | 0.030 |
Why?
| | Oscillometry | 1 | 2015 | 7 | 0.030 |
Why?
| | Health Literacy | 1 | 2017 | 132 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2017 | 204 | 0.030 |
Why?
| | NAD | 1 | 2015 | 45 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 66 | 0.030 |
Why?
| | Arm | 1 | 2015 | 47 | 0.030 |
Why?
| | Systole | 1 | 2015 | 71 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2015 | 89 | 0.030 |
Why?
| | Observer Variation | 1 | 2015 | 138 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 103 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2015 | 197 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 109 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 1031 | 0.030 |
Why?
| | Suramin | 1 | 2014 | 10 | 0.030 |
Why?
| | Fas Ligand Protein | 1 | 2014 | 16 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2014 | 8 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2014 | 27 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2014 | 61 | 0.030 |
Why?
| | Algorithms | 1 | 2018 | 667 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2015 | 201 | 0.030 |
Why?
| | Gene Silencing | 1 | 2014 | 122 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2014 | 81 | 0.030 |
Why?
| | Biological Availability | 2 | 2005 | 107 | 0.030 |
Why?
| | Pentanones | 1 | 2013 | 7 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2014 | 174 | 0.030 |
Why?
| | Capsules | 1 | 2013 | 29 | 0.030 |
Why?
| | Powders | 1 | 2013 | 26 | 0.030 |
Why?
| | Paper | 1 | 2013 | 16 | 0.030 |
Why?
| | Methylamines | 1 | 2013 | 23 | 0.030 |
Why?
| | Ethanol | 1 | 2016 | 338 | 0.020 |
Why?
| | Body Temperature Regulation | 1 | 2013 | 29 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2013 | 40 | 0.020 |
Why?
| | Pyrrolidines | 1 | 2013 | 65 | 0.020 |
Why?
| | Hallucinogens | 1 | 2013 | 58 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 193 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 89 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 600 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 17 | 0.020 |
Why?
| | Drug Resistance | 1 | 2012 | 71 | 0.020 |
Why?
| | Placebo Effect | 1 | 2012 | 16 | 0.020 |
Why?
| | Amine Oxidase (Copper-Containing) | 1 | 2012 | 3 | 0.020 |
Why?
| | Prescription Drugs | 1 | 2012 | 40 | 0.020 |
Why?
| | Interleukin-3 | 1 | 2012 | 12 | 0.020 |
Why?
| | Fever | 1 | 2013 | 112 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 23 | 0.020 |
Why?
| | Intention to Treat Analysis | 1 | 2012 | 30 | 0.020 |
Why?
| | Histamine | 1 | 2012 | 24 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 361 | 0.020 |
Why?
| | Protein Precursors | 1 | 2012 | 42 | 0.020 |
Why?
| | Dopamine | 1 | 2013 | 167 | 0.020 |
Why?
| | Calcitonin | 1 | 2012 | 30 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 880 | 0.020 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2012 | 50 | 0.020 |
Why?
| | Population | 1 | 2012 | 8 | 0.020 |
Why?
| | Office Visits | 1 | 2012 | 45 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 124 | 0.020 |
Why?
| | Ligands | 1 | 2012 | 203 | 0.020 |
Why?
| | Hyperthermia, Induced | 1 | 2013 | 114 | 0.020 |
Why?
| | Expectorants | 1 | 2011 | 14 | 0.020 |
Why?
| | Risk | 1 | 2012 | 306 | 0.020 |
Why?
| | Central Nervous System | 1 | 2012 | 76 | 0.020 |
Why?
| | Glucuronic Acid | 1 | 2011 | 11 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2012 | 89 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 158 | 0.020 |
Why?
| | Microsomes | 1 | 2011 | 35 | 0.020 |
Why?
| | ROC Curve | 1 | 2012 | 246 | 0.020 |
Why?
| | Deuterium | 1 | 2011 | 47 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 52 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 89 | 0.020 |
Why?
| | Syndrome | 1 | 2012 | 248 | 0.020 |
Why?
| | Birth Weight | 1 | 2012 | 119 | 0.020 |
Why?
| | Cytoplasm | 1 | 2011 | 93 | 0.020 |
Why?
| | Forensic Toxicology | 1 | 2011 | 4 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2012 | 152 | 0.020 |
Why?
| | Muscular Dystrophies | 1 | 2011 | 14 | 0.020 |
Why?
| | Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2011 | 9 | 0.020 |
Why?
| | Glucuronidase | 1 | 2011 | 47 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 598 | 0.020 |
Why?
| | Forecasting | 1 | 2012 | 152 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2011 | 124 | 0.020 |
Why?
| | Crime | 1 | 2011 | 28 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2011 | 94 | 0.020 |
Why?
| | Transaminases | 1 | 2011 | 12 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 43 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2012 | 243 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 587 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2012 | 729 | 0.020 |
Why?
| | Intestines | 1 | 2011 | 159 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 158 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2011 | 229 | 0.020 |
Why?
| | Body Mass Index | 1 | 2013 | 717 | 0.020 |
Why?
| | Child Development | 1 | 2012 | 215 | 0.020 |
Why?
| | Suction | 1 | 2009 | 22 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 1544 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2011 | 241 | 0.020 |
Why?
| | Eating | 1 | 2009 | 159 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 466 | 0.020 |
Why?
| | Kidney | 1 | 2013 | 715 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 949 | 0.020 |
Why?
| | Alcoholism | 1 | 2011 | 242 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 64 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 815 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2008 | 212 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2008 | 346 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2009 | 2318 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 28 | 0.010 |
Why?
| | Specialization | 1 | 2003 | 48 | 0.010 |
Why?
| | Medicine | 1 | 2003 | 51 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 452 | 0.010 |
Why?
| | Endopeptidases | 1 | 2002 | 62 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|